[Hormone receptor testing in breast cancer]
Secco A, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001489
Original Title: Determinación de receptores hormonales en cáncer de mama
Authors' recomendations: CONCLUSIONS Moderate-quality evidence shows a high benefit of hormone (estrogen and progesterone) receptor testing by immunohistochemistry as markers of prognosis and response to hormone therapy in breast cancer, in primary tumors, recurrences or metastases. In the last two, the importance of testing them lies on the possibility of conversion in terms of the primary tumor. Moderate-quality evidence shows that those patients with a receptor test result below 10% would benefit with the use of hormone therapy although they would have a better prognosis than those with negative receptors. Most of the clinical practice guidelines consulted recommend testing them to assess prognosis and response to hormone therapy, both in the primary tumor and in relapses, defining tumors with positive hormone receptors when the expression is above or equal to 1%. In Argentina, The Mandatory Medical Plan covers it in order to define the hormone therapy indication and its potential response level and to determine the breast cancer prognosis. The rest of the coverage policies consulted in Latin America do not mention the technology. Most coverage policies from United States and Europe private and public sponsors consulted do not mention or cover this technology.
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Breast Neoplasms
- Biomarkers, Tumor
- Neoplasms, Hormone-Dependent
- Receptors, Estrogen
- Receptors, Progesterone
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.